FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385409094> ?p ?o ?g. }

• W4385409094 abstract "Abstract Background The aim of this observational, real-world evidence, modified intention-to-treat (mITT) study based on prospectively collected data from the VEDOIBD registry was to compare the effectiveness of vedolizumab (VEDO) vs antitumor necrosis factor (anti-TNF) in biologic-naïve Crohn’s disease (CD) patients. Methods Between 2017 and 2020, 557 CD patients starting therapy with VEDO or anti-TNF were consecutively enrolled in 45 IBD centers across Germany. Per study protocol, the analysis excluded biologic-experienced patients and those with a missing Harvey-Bradshaw Index score, resulting in a final sample of 327 biologic-naïve CD patients. Clinical remission was measured using the Harvey-Bradshaw Index at the end of induction therapy and after 1 and 2 years. Switching to a different therapy was considered an outcome failure. Propensity score adjustment with inverse probability of treatment weighting was used to correct for confounding. Results The effectiveness of both VEDO (n = 86) and anti-TNF (n = 241) was remarkably high for induction treatment, but VEDO performed significantly less well than anti-TNF (clinical remission: 56.3% vs 73.9%, P &lt; .05). In contrast, clinical remission after 2 years was significantly better for VEDO compared with anti-TNF (74.2% vs 44.7%; P &lt; .05; odds ratio, 0.45; 95% CI, 0.22-0.94). Remarkably, only 17% of patients switched from VEDO to another biologic vs 44% who received anti-TNF. Conclusions The results of this prospective, 2-year, real-world evidence study suggest that the choice of VEDO led to higher remission rates after 2 years compared with anti-TNF. This could support the role of VEDO as a first-line biologic therapy in CD." @default.
• W4385409094 created "2023-08-01" @default.
• W4385409094 creator A5006205653 @default.
• W4385409094 creator A5008840756 @default.
• W4385409094 creator A5022726213 @default.
• W4385409094 creator A5024613920 @default.
• W4385409094 creator A5027590030 @default.
• W4385409094 creator A5028800598 @default.
• W4385409094 creator A5028928773 @default.
• W4385409094 creator A5034003178 @default.
• W4385409094 creator A5039233962 @default.
• W4385409094 creator A5058697669 @default.
• W4385409094 creator A5059435501 @default.
• W4385409094 creator A5061864013 @default.
• W4385409094 creator A5073088783 @default.
• W4385409094 creator A5078104404 @default.
• W4385409094 creator A5086407570 @default.
• W4385409094 date "2023-07-31" @default.
• W4385409094 modified "2023-09-27" @default.
• W4385409094 title "Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn’s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study" @default.
• W4385409094 cites W1542603097 @default.
• W4385409094 cites W2049244358 @default.
• W4385409094 cites W2053148876 @default.
• W4385409094 cites W2077531651 @default.
• W4385409094 cites W2103963141 @default.
• W4385409094 cites W2130947879 @default.
• W4385409094 cites W2217417039 @default.
• W4385409094 cites W2290094568 @default.
• W4385409094 cites W2301614008 @default.
• W4385409094 cites W2427633307 @default.
• W4385409094 cites W2766046358 @default.
• W4385409094 cites W2782570247 @default.
• W4385409094 cites W2790992948 @default.
• W4385409094 cites W2806806868 @default.
• W4385409094 cites W2807902520 @default.
• W4385409094 cites W2914394532 @default.
• W4385409094 cites W2914936826 @default.
• W4385409094 cites W2936468435 @default.
• W4385409094 cites W2949132681 @default.
• W4385409094 cites W2950457069 @default.
• W4385409094 cites W2952365135 @default.
• W4385409094 cites W2976731348 @default.
• W4385409094 cites W3037634475 @default.
• W4385409094 cites W3040906189 @default.
• W4385409094 cites W3041424716 @default.
• W4385409094 cites W3115410759 @default.
• W4385409094 cites W3149611511 @default.
• W4385409094 cites W3157958883 @default.
• W4385409094 cites W4200263952 @default.
• W4385409094 cites W4211167126 @default.
• W4385409094 cites W4213088258 @default.
• W4385409094 cites W4221063101 @default.
• W4385409094 cites W4225473765 @default.
• W4385409094 cites W4281951137 @default.
• W4385409094 cites W4282048809 @default.
• W4385409094 doi "https://doi.org/10.1093/ibd/izad138" @default.
• W4385409094 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37523666" @default.
• W4385409094 hasPublicationYear "2023" @default.
• W4385409094 type Work @default.
• W4385409094 citedByCount "0" @default.
• W4385409094 crossrefType "journal-article" @default.
• W4385409094 hasAuthorship W4385409094A5006205653 @default.
• W4385409094 hasAuthorship W4385409094A5008840756 @default.
• W4385409094 hasAuthorship W4385409094A5022726213 @default.
• W4385409094 hasAuthorship W4385409094A5024613920 @default.
• W4385409094 hasAuthorship W4385409094A5027590030 @default.
• W4385409094 hasAuthorship W4385409094A5028800598 @default.
• W4385409094 hasAuthorship W4385409094A5028928773 @default.
• W4385409094 hasAuthorship W4385409094A5034003178 @default.
• W4385409094 hasAuthorship W4385409094A5039233962 @default.
• W4385409094 hasAuthorship W4385409094A5058697669 @default.
• W4385409094 hasAuthorship W4385409094A5059435501 @default.
• W4385409094 hasAuthorship W4385409094A5061864013 @default.
• W4385409094 hasAuthorship W4385409094A5073088783 @default.
• W4385409094 hasAuthorship W4385409094A5078104404 @default.
• W4385409094 hasAuthorship W4385409094A5086407570 @default.
• W4385409094 hasConcept C126322002 @default.
• W4385409094 hasConcept C156957248 @default.
• W4385409094 hasConcept C17923572 @default.
• W4385409094 hasConcept C23131810 @default.
• W4385409094 hasConcept C2776207728 @default.
• W4385409094 hasConcept C2777138892 @default.
• W4385409094 hasConcept C2778260677 @default.
• W4385409094 hasConcept C2779134260 @default.
• W4385409094 hasConcept C2779280984 @default.
• W4385409094 hasConcept C71924100 @default.
• W4385409094 hasConcept C77350462 @default.
• W4385409094 hasConcept C90924648 @default.
• W4385409094 hasConceptScore W4385409094C126322002 @default.
• W4385409094 hasConceptScore W4385409094C156957248 @default.
• W4385409094 hasConceptScore W4385409094C17923572 @default.
• W4385409094 hasConceptScore W4385409094C23131810 @default.
• W4385409094 hasConceptScore W4385409094C2776207728 @default.
• W4385409094 hasConceptScore W4385409094C2777138892 @default.
• W4385409094 hasConceptScore W4385409094C2778260677 @default.
• W4385409094 hasConceptScore W4385409094C2779134260 @default.
• W4385409094 hasConceptScore W4385409094C2779280984 @default.
• W4385409094 hasConceptScore W4385409094C71924100 @default.
• W4385409094 hasConceptScore W4385409094C77350462 @default.
• W4385409094 hasConceptScore W4385409094C90924648 @default.

• next